KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Medpace Holdings (MEDP) EBIAT (2016 - 2025)

Medpace Holdings (MEDP) has disclosed EBIAT for 11 consecutive years, with $135.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT rose 15.48% year-over-year to $135.1 million, compared with a TTM value of $451.1 million through Dec 2025, up 11.56%, and an annual FY2025 reading of $451.1 million, up 11.56% over the prior year.
  • EBIAT was $135.1 million for Q4 2025 at Medpace Holdings, up from $111.1 million in the prior quarter.
  • Across five years, EBIAT topped out at $135.1 million in Q4 2025 and bottomed at $39.9 million in Q2 2021.
  • Average EBIAT over 5 years is $78.2 million, with a median of $71.7 million recorded in 2023.
  • Peak annual rise in EBIAT hit 65.67% in 2021, while the deepest fall reached 1.64% in 2021.
  • Year by year, EBIAT stood at $50.0 million in 2021, then soared by 37.25% to $68.7 million in 2022, then increased by 14.02% to $78.3 million in 2023, then skyrocketed by 49.45% to $117.0 million in 2024, then grew by 15.48% to $135.1 million in 2025.
  • Business Quant data shows EBIAT for MEDP at $135.1 million in Q4 2025, $111.1 million in Q3 2025, and $90.3 million in Q2 2025.